Krystal Biotech Dividends and Buybacks
Dividend criteria checks 0/6
Krystal Biotech does not have a record of paying a dividend.
Key information
n/a
Dividend yield
-0.5%
Buyback Yield
| Total Shareholder Yield | -0.5% |
| Future Dividend Yield | 0% |
| Dividend Growth | n/a |
| Next dividend pay date | n/a |
| Ex dividend date | n/a |
| Dividend per share | n/a |
| Payout ratio | n/a |
Recent dividend and buyback updates
No updates
Recent updates
Krystal Biotech, Inc. (NASDAQ:KRYS) Third-Quarter Results Just Came Out: Here's What Analysts Are Forecasting For Next Year
Nov 07
Krystal Biotech: Q4 Catalysts Expected With VYJUVEK Revenue Growth Pressing On
Oct 14Krystal Biotech: High Valuation Merits Caution Ahead Of Q2 Earnings (Rating Downgrade)
Jul 31Krystal Biotech's (NASDAQ:KRYS) Earnings Might Be Weaker Than You Think
May 13Krystal Biotech's Future Brightens With Vyjuvek's Robust Launch
Feb 28Krystal Biotech: Ready For Launch
Feb 20We Think Krystal Biotech (NASDAQ:KRYS) Can Easily Afford To Drive Business Growth
Jan 02Companies Like Krystal Biotech (NASDAQ:KRYS) Can Afford To Invest In Growth
Sep 06Are Investors Undervaluing Krystal Biotech, Inc. (NASDAQ:KRYS) By 46%?
Aug 08We Think Krystal Biotech (NASDAQ:KRYS) Can Afford To Drive Business Growth
May 17We're Hopeful That Krystal Biotech (NASDAQ:KRYS) Will Use Its Cash Wisely
Jan 30Krystal Biotech cleared to file EU marketing application for rare skin disease therapy
Sep 22We Think Krystal Biotech (NASDAQ:KRYS) Can Afford To Drive Business Growth
Aug 30Krystal Biotech: Solid Performance, Let's Keep Holding
Aug 18Krystal Biotech GAAP EPS of -$1.10 misses by $0.07
Aug 08Krystal gets FDA nod to start trial of gene therapy KB407 for cystic fibrosis
Aug 01Krystal Biotech: High Potential, Buy-At-Dips Stock
May 25We're Hopeful That Krystal Biotech (NASDAQ:KRYS) Will Use Its Cash Wisely
Apr 20Krystal Biotech: The Future Looks More And More Derisked
Feb 21Krystal Biotech Establishes Proof Of Concept With STAR-D Platform; Opens Door For More Skin Indications
Nov 30Krystal Biotech: A Buy Ahead Of Their Pivotal DEB P3 Trial Readout
Sep 27Here's Why We're Not Too Worried About Krystal Biotech's (NASDAQ:KRYS) Cash Burn Situation
Sep 25Stability and Growth of Payments
Fetching dividends data
Stable Dividend: Insufficient data to determine if KRYS's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if KRYS's dividend payments have been increasing.
Dividend Yield vs Market
| Krystal Biotech Dividend Yield vs Market |
|---|
| Segment | Dividend Yield |
|---|---|
| Company (KRYS) | n/a |
| Market Bottom 25% (US) | 1.4% |
| Market Top 25% (US) | 4.4% |
| Industry Average (Biotechs) | 2.2% |
| Analyst forecast (KRYS) (up to 3 years) | 0% |
Notable Dividend: Unable to evaluate KRYS's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate KRYS's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate KRYS's payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as KRYS has not reported any payouts.